Santiago Arroyo Sells 26,954 Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Stock

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) SVP Santiago Arroyo sold 26,954 shares of Momenta Pharmaceuticals stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $15.91, for a total transaction of $428,838.14. The sale was disclosed in a document filed with the SEC, which is available through this link.

Santiago Arroyo also recently made the following trade(s):

  • On Friday, October 18th, Santiago Arroyo sold 6,318 shares of Momenta Pharmaceuticals stock. The shares were sold at an average price of $13.83, for a total transaction of $87,377.94.

Shares of MNTA opened at $16.41 on Friday. The company’s fifty day moving average price is $14.12 and its 200 day moving average price is $12.82. Momenta Pharmaceuticals, Inc. has a one year low of $9.51 and a one year high of $16.65. The company has a market capitalization of $1.46 billion, a PE ratio of -8.08 and a beta of 2.07.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Thursday, October 31st. The biotechnology company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.09). Momenta Pharmaceuticals had a negative net margin of 361.66% and a negative return on equity of 59.82%. The business had revenue of $6.40 million for the quarter, compared to analyst estimates of $5.24 million. During the same quarter last year, the firm posted ($0.65) earnings per share. Momenta Pharmaceuticals’s revenue was down 57.0% on a year-over-year basis. As a group, equities research analysts forecast that Momenta Pharmaceuticals, Inc. will post -2.59 EPS for the current year.

A number of research firms have recently weighed in on MNTA. Stifel Nicolaus restated a “buy” rating and set a $29.00 price target on shares of Momenta Pharmaceuticals in a report on Thursday, October 24th. HC Wainwright began coverage on shares of Momenta Pharmaceuticals in a report on Wednesday, September 25th. They set a “buy” rating and a $24.00 price target on the stock. BidaskClub upgraded shares of Momenta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, October 31st. Piper Jaffray Companies set a $35.00 price target on shares of Momenta Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, September 17th. Finally, ValuEngine upgraded shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Momenta Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $22.53.

A number of large investors have recently added to or reduced their stakes in the business. Arizona State Retirement System boosted its position in Momenta Pharmaceuticals by 0.7% in the second quarter. Arizona State Retirement System now owns 152,967 shares of the biotechnology company’s stock valued at $1,904,000 after buying an additional 1,003 shares in the last quarter. United Services Automobile Association boosted its position in Momenta Pharmaceuticals by 0.9% in the second quarter. United Services Automobile Association now owns 218,633 shares of the biotechnology company’s stock valued at $2,722,000 after buying an additional 1,890 shares in the last quarter. CWM Advisors LLC boosted its position in Momenta Pharmaceuticals by 17.2% in the second quarter. CWM Advisors LLC now owns 13,780 shares of the biotechnology company’s stock valued at $172,000 after buying an additional 2,020 shares in the last quarter. Oregon Public Employees Retirement Fund boosted its position in Momenta Pharmaceuticals by 5.6% in the second quarter. Oregon Public Employees Retirement Fund now owns 39,254 shares of the biotechnology company’s stock valued at $489,000 after buying an additional 2,074 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Momenta Pharmaceuticals by 68.1% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,625 shares of the biotechnology company’s stock valued at $95,000 after buying an additional 3,088 shares in the last quarter. Hedge funds and other institutional investors own 96.30% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

See Also: Resistance Level

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.